Tests L-Citrulline, BH4 and atorvastatin for blood vessel function in Veterans with HFpEF
Tests L-Citrulline, BH4 and atorvastatin on exercise ability and vessels in Veterans.
Plain-language title generated from the registry record
Registry title: Novel Approaches for Improving Vascular Function in Veterans With HFpEF
Key facts
- Where
- Salt Lake City, United StatesSee the site
- Phase
- Phase 1
Where in United States
- VA Salt Lake City Health Care System, Salt Lake City, UTSalt Lake City, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- VA Office of Research and Development
- Trial code
- NCT06312748
- Record updated
- 23 April 2026
- Original description
This project will evaluate the impact of L-Citrulline, tetrahydrobiopterin (BH4), and atorvastatin administration on physical capacity and vascular function in Veterans with heart failure with preserved ejection fraction (HFpEF).Read full original descriptionShow less
Novel Approaches for Improving Vascular Function in Veterans With HFpEF
This project will evaluate the impact of L-Citrulline, tetrahydrobiopterin (BH4), and atorvastatin administration on physical capacity and vascular function in Veterans with heart failure with preserved ejection fraction (HFpEF).
Inclusion: Age 18 years or older and able to give written informed consent; New York Heart Association (NYHA) functional class I, II, or III; Left Ventricular Ejection Fraction (LVEF) > 50%; Plasma Brain Natriuretic Peptide (BNP) equal to or greater than 150 pg/mL or NT-proBNP equal to or greater than 600 pg/mL at Visit 1, or a BNP equal to or great than 100 pg/mL (or NT-proBNP equal to or greater than 400 pg/mL) and a hospitalization for heart failure within the last 12 months.
Exclusion: Prior EF <50%; Patients currently treated with antioxidants, nitrates, PDE-5 inhibitors, or statins; History of hypersensitivity or allergy to any lipophilic statin; Patients with HFpEF secondary to significant uncorrected primary valvular disease; Active liver disease or unexplained persistent elevations in serum transaminase; NYHA Class IV; Women who are pregnant or may become pregnant.